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Cell death inside articular cartilage was examined by TUNEL assay.
Expression of catabolic, inﬂammatory, and anabolic factors such as
MMP3, MMP13, cathepsin F, IL1b, IL6, type II collagen and type X col-
lagen mRNA in cartilagious tissues of :7CKO and Cont mice was quan-
titated by Q-PCR.
Results: In this study, we found that the absence of locally produced
Bmp7 reduced proteoglycan contents in articular cartilage matrix in the
adult mice (at 8 and 24 weeks of age). This may not be due to the defect
in cartilage formation since there was no signiﬁcant alteration in both
articular structure and proteoglycan contents in the juvenile :7CKO
mice (at 4 weeks of age). Structural analyses of articular cartilage
indicated that cartilage thickness and chondrocyte density were not
signiﬁcantly altered between the genotypes at 8 and 24 weeks of age.
TUNEL assay revealed that elimination of Bmp7 expression did not
affect chondrocyte survival at 8 weeks of age. Histological evaluation
revealed that extensive synovial hyperplasia was observed at 8 and 24
weeks of age in the absence of Bmp7. F4/80 staining revealed that
extensive numbers of macrophages were inﬁltrated in the synovial
tissues of :7CKO mice at these stages suggesting that severe synovitis
occurred in the absence of Bmp7. In contrast, appearance of synovial
membrane was quite similar between the genotypes at 4 weeks of age.
Q-PCR analyses revealed that mRNA expression levels of all the genes
examined (see above) in articular cartilage were not signiﬁcantly
altered between the genotypes at 24 weeks of age.
Conclusions: Our data showed that the absence of endogenous Bmp7,
although does not affect articular cartilage formation and survival of
articular chondrocyte, but enhance articular cartilage degeneration and
synovial inﬂammation in adult mice.
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EPIGENETIC MODIFYING COMPOUNDS ALTER ACTIVITY OF PRIMARY
HUMAN ARTICULAR CHONDROCYTES AND MESENCHYMAL STEM
CELLS UNDERGOING CHONDROGENESIS
S. Snelling, A. Kramm, C. Yapp, A. Carr, U. Oppermann. Univ. of Oxford,
Oxford, United Kingdom
Purpose: A major therapeutic challenge in osteoarthritis is to identify
disease modifying therapeutics. No current therapies cause cessation or
reversal of cartilage loss. Suitable therapeutics may target the chon-
drocytes or stem cells resident within the diseased cartilage or expan-
ded in vitro prior to implantation. Epigenetic regulation of cell behavior
is essential for both correct development and homeostasis of cartilage
(1). This epigenetic control does not alter the DNA sequence and allows
modiﬁable changes to gene expression that are heritable. Thus allowing
a cell to respond to environmental and biological cues. Targeting the
epigenetic modifying machinery can therefore provide important clues
to the biology of chondrocyte differentiation and homeostasis and to
potential targets for therapeutic intervention.
Our library of epigenetic modifying compounds includes those target-
ing methyltrasnferases, histone deacetylases, histone protein kinases
and bromodomains. In this preliminary work we have screened this
library for impact on cell phenotype in chondrogenesis and in primary
human articular chondrocytes (HAC)
Methods: Primary human articular chondrocytes (HAC) and human
mesencymal stem cells (MSCs) undergoing chondrogenesis were trea-
ted with epigenetic modifying compounds for 72 hours. Metabolic
activity was assessed after 72h using Prestoblue before cells were ﬁxed
and assessed for cell number (DAPI count), ECM production (Alcian
blue) and nodule formation (Nile Red). HAC were treated with GSK-J4
and GSK-J5 for 6h and TIMP3 and COL2A1 expression assessed by qPCR.
HAC were treated with GSK-J4 and GSK-J5 for 3h in the presence and
absence of 2ng/ml TGFb and expression JMJD3 and the TGFb target gene
TIMP3 was assssed by qPCR.
Results: Compounds including Methylstat, an inhibitor of the Jumonji C
domain-containing histone trimethyl demethylases caused an increase
in the metabolic activity and cell number of MSCs and HAC, whilst 5-
iodotubercidin increasedmetabolic activity inMSCs only. GSK-J4, which
blocks H3K27 demethylation decreased metabolic activity and cell
number in MSCs and HAC. ECM accumulation in chondrogenesis were
reduced by compounds including GSK-J4 whilst ECM accumulation was
increased by the PARP inhibitor Rucaparib.
COL2A1 and TIMP3 expressionwas reduced in HAC treated with GSK-J4,
but not HAC treated with the inactive isomer GSK-J5. Treatment of HAC
with TGFb increased the expression of the H3K27 demethylase JMJD3and the TGF-responsive gene TIMP3. In the presence of GSK-J4 the TGF-
induced JMJD3 and TIMP3 expression was inhibited.
Conclusions: This preliminary screen demonstrates the utility of epi-
genetic modifying compounds in the regulation of chondrogenesis and
HAC behavior. We have shown that epigenetic regulation can both
enhance and inhibit chondrogenesis and can also alter the phenotype of
HAC. The differential effects of compounds in HAC and MSC indicates
the importance of ﬁne and temporally correct regulation of epigenetic
activities during chondrocyte differentiation and homeostasis. Early
investigations on the role of GSK-J4, which inhibits the histone deme-
thylase JMJD3, in HAC suggest JMJD3 as an important epigenetic target
through its ability to regulate TGFb signaling.
227
FIBRILLIN-1 EXPRESSION, WHICH REGULATES OF TGF-B
BIOAVAILABILITY, IS MODIFIED DURING OSTEOARTHRITIS AND
MUTATIONS LEAD TO OSTEOARTHRITIS
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Purpose: The TGFb signalling pathway has been shown to play a major
role in joint homeostasis and in osteoarthritis development. Fibrillin-1
is an extracellular matrix protein that may play a structural role in the
matrix of articular cartilage. Fibrillin rich microﬁbrils (especially
ﬁbrillin-1) help in the regulation of TGFb activity by controlling its
bioavailability to the cell. Thus Fibrillin-1 mutations, such as those
seen in the Tight Skin mouse (or TSK), have been shown to increase
TGFb signalling. The TSK mouse displays tight skin, myocardial
hypertrophy, marfan-like skeletal phenotype and lung emphysema,
but no studies have yet investigated the effect of Fibrillin-1 mutation
on joint health. The aim of this study is therefore to determine
changes in ﬁbrillin-1 expression during osteoarthritis in mice and to
characterise the effect of Fibrillin-1 mutations in ageing-induced OA
development in TSK mice.
Methods: Immunohistochemistry for Fibrillin-1 expression was per-
formed in Str/ort mice, a known model of spontaneous OA, and in
control aged-matched non-OA CBA mice, in knee joints with different
degrees of OA severity. The knees of TSK and littermate control male
mice of 60-80wks of age were ﬁxed and microCT scanned. Abnormal
ectopic calciﬁed regions were analysed. After scanning, joints were
decalciﬁed and processed for parafﬁn embedding; serial coronal sec-
tions were cut at 6um and sections at regular intervals stained with
Toluidine Blue.
Results: Fibrillin-1 was localised in the pericellular matrix of articular
chondrocytes in normal joints. During the development of OA in Str/ort
mice, however, Fibrillin-1 immunolabelling was decreased, in particular
around articular cartilage lesions. TSK mice microCT images showed
important ectopic calciﬁcation and ossiﬁcation in various ligaments,
including patella and collateral ligaments, as well as osteophyte for-
mation on the margins of the joints. Preliminary data suggest that
articulate cartilage degradation was increased in TSK mice compared to
aged-matched control mice suggesting a role of Fibrillin-1 in joint
health and osteoarthritis development.
Conclusion: Our preliminary study shows that Fibrillin-1 protein
expression is decreased during OA development in a well knownmodel
of spontaneous OA, suggesting TGFb bioavailability may be modiﬁed
during this period. In addition, mutations in Fibrillin-1 in the TSK
mouse lead to abnormal ossiﬁcation in the knee joint as well as severe
OA development. These data suggest that Fibrillin-1 plays an important
role in joint homeostasis and that abnormal expression or mutations in
its gene can lead to OA development.
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DYNAMIC CHANGES OF EXTRA CELLULAR MATRIX PROTEINS IN
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